Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Ellen K. Ritchie, Richard A. Larson, Catherine Choy Smith, Eunice S. Wang, Stephen Anthony Strickland, Maria R. Baer, Mark Robert Litzow, David Claxton, Gary J. Schiller, Celalettin Ustun, Charles Liu, Stan Gill, Briana Sargent, Erkut Bahceci
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Pennsylvania, Northwestern University, The University of Texas MD Anderson Cancer Center, Cornell University, Weill Cornell Medicine, University of Chicago, University of California, San Francisco, Roswell Park Comprehensive Cancer Center, Vanderbilt University Medical Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Mayo Clinic, Penn State Milton S. Hershey Medical Center, University of California, Los Angeles, University of Minnesota, Astellas Pharma (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2199743809